Lupus & antiphospholipid syndrome
DNA methylation alterations in systemic lupus erythematosus: A systematic review of case-control studies
Authors' conclusion
The methylation status of some genes especially IFI44L, FOXP3, and MX1 has been suggested as promising SLE biomarkers. However, given the conflicting findings between studies because of potential confounders such as different sample types, methylation profiling methods, and ethnicity as well as shared DNA methylation patterns of SLE and other autoimmune diseases, DNA methylation biomarkers are currently not reliable diagnostic biomarkers and do not represent surrogate markers of SLE disease activity.
Study context
- Population
- Case-control studies assessing DNA methylation of specific genes in systemic lupus erythematosus (SLE) vs healthy controls; PubMed, Scopus, Google Scholar up to July 202244 studies
- Participants
- 3,471 vs 1,028
- Comparison
- SLE patients vs healthy controls
- SLEn = 3,471
- Healthy controlsn = 1,028reference
- Outcome
- DNA methylation alterations in SLE vs healthy controls
Methodological detailsnon-high-throughput methylation techniques only, quality of bias assessment
- Non-high-throughput methylation techniques only
- Quality of bias assessment
Pooled result
As reported in the abstract
Sensitivity, specificity and diagnostic power of methylation levels reported only for IFI44L
5 studies
Correlation between methylation patterns and clinical parameters explored
22 studies
Remarkable association between DNA methylation status and clinical indices
16 publications
Further pooled results
Study and patient characteristics
- Female, among studies reporting gender (n = 2853)
- 89.41%
- Male, among studies reporting gender (n = 2853)
- 10.59%
- Studies in adult patients
- 40
- Studies on whole blood or PBMCs
- 22
- Studies on unfractionated white blood cells
- 2
- Studies on sorted blood cells
- 20
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →